Drug Profile
BMS 986179
Alternative Names: BMS-986179Latest Information Update: 05 Jul 2016
Price :
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 01 Jun 2016 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Combination therapy) in USA (IV) (NCT02754141)
- 22 Apr 2016 Preclinical trials in Solid tumours in USA (IV) before April 2016